Skip to main content

Advertisement

Table 1 Baseline patient characteristics

From: Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Characteristic N = 855
Median age, years (range) 61 (16–88)
Male/female, n (%) 460 (54)/395 (46)
ECOG PS, n (%)  
 0 563 (66)
 1 267 (31)
 2 25 (3)
Time from diagnosis, months (range) 39 (3–280)
Tumour subtype  
 Cutaneous 631 (74)
 Mucosal 71 (8)
 Ocular 83 (10)
 Primary origin unknown 70 (8)
Patients with brain metastases, n (%) 146 (17)
Patients with liver metastases, n (%) 339 (40)
Elevated LDH (≥1.10 ULN), n/n (%) 276/720 (38)
BRAF-mutation positive, n/n (%) 173/469 (37)
NRAS-mutation positive, n/n (%) 14/82 (17)
Number of previous therapies:  
 1 497 (58)
 2 233 (27)
 ≥3 125 (15)
Previous therapy, n (%)  
 Dacarbazine 490 (57)
 Fotemustine 322 (38)
 Platinum-based chemotherapy 316 (37)
 Paclitaxel 78 (9)
 Temozolomide 189 (22)
 Interferon 192 (22)
 BRAF inhibitor 59 (7)
  1. ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; ULN: upper limit of normal.